Please assess the completion status of the following clinical trial:

Trial Title: Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have precursor-B lymphoblastic leukemia or lymphoma.~2. Patients must be untreated or have had only one prior chemotherapy regimen for ALL or LL . Previously treated patients will be analyzed separately.~3. Age between 12 to 30 years old~4. Patients with central nervous system (CNS) disease or testicular disease are eligible.~5. Intrathecal therapy with cytarabine is allowed prior to registration for patient convenience. This is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture. Systemic chemotherapy must begin within 72 hours of the first intrathecal treatment.~6. Signed informed consent prior to the start of systemic therapy. In the event of enrollment of a minor patient, an attempt to obtain assent from the patient must be documented, and parental consent must be signed.~7. Echocardiogram should be done within 7 days of starting therapy if there are cardiac risk factors (e.g., history of hypertension or of myocardial infarction)~8. Creatinine should be \< 3 mg/dL bilirubin \< 3 mg/dl unless due to disease~9. Zubrod Performance status of \<3~10. Patients who received steroids more than 72 hours prior to study enrollment are eligible but will be analyzed separately.~11. Lymphoblasts may have any positive expression of cluster of differentiation antigen 20 (CD20) for ofatumumab administration.~Exclusion Criteria:~1. Age less than twelve years of age or greater than 30 years.~2. More than one prior treatment regimen for ALL or LL.~3. The patient is pregnant or unwilling to practice appropriate birth control.~4. Presence of the Philadelphia chromosome t(9;22)~5. Laboratory or clinical evidence of active infectious hepatitis.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Augmented BFM Therapy + Ofatumumab or Rituximab (Type: EXPERIMENTAL): Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).